Microbot Medical (MBOT) Receiving Somewhat Favorable Media Coverage, Accern Reports
Media stories about Microbot Medical (NASDAQ:MBOT) have trended somewhat positive recently, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Microbot Medical earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 44.7239434536407 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Microbot Medical Inc. (MBOT) is at $1.28 per share and MyoKardia, Inc. (MYOK) is listed at $48.70 – Stocks Gallery (stocksgallery.com)
- Microbot Medical Inc. (MBOT) Director Yoseph Bornstein Sells 50,000 Shares (americanbankingnews.com)
- Rare Stocks Roar Again After Tech Valuation: Microbot Medical Inc. (NASDAQ:MBOT) – NASDAQ Times (nasdaqtimes.com)
- 11470644 shares of Microbot Medical Inc. (MBOT) changed at hands actively on Sep 15, 2017 – Voice Of Analysts (analystsbuzz.com)
- Microbot Medical Inc (MBOT) Receives $198 Consensus Target Price – ExpertGazette (expertgazette.com)
Microbot Medical (NASDAQ:MBOT) traded down 0.379% during mid-day trading on Monday, hitting $1.315. 1,228,464 shares of the stock traded hands. Microbot Medical has a one year low of $1.00 and a one year high of $15.66. The stock’s market capitalization is $57.91 million. The company has a 50 day moving average price of $1.10 and a 200-day moving average price of $3.03.
Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.44. Equities analysts anticipate that Microbot Medical will post ($25.02) earnings per share for the current fiscal year.
Separately, ValuEngine raised shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd.
COPYRIGHT VIOLATION WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/09/25/microbot-medical-mbot-receiving-somewhat-favorable-media-coverage-accern-reports.html.
In related news, Director Yoseph Bornstein sold 50,000 shares of Microbot Medical stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $1.18, for a total transaction of $59,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 115,610 shares of company stock worth $127,466 over the last ninety days. 31.83% of the stock is currently owned by insiders.
Microbot Medical Company Profile
Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.
Receive News & Ratings for Microbot Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.